Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitoxantrone hydrochloride liposome injection versus chidamide monotherapy for relapsed or refractory peripheral T-cell lymphoma
CTR20202403Phase 3Active
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- May 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of mitoxantrone in peripheral T-cell lymphoma (PTCL), sponsored by CSPC ZhongQi Pharmaceutical Technology. Started May 2021; status: active.
02
Drugs
mitoxantrone
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on CTR20202403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202403.